Develop therapeutics for the treatment of cancer. Focus on Validive, a treatment for oral mucositis. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
There is $140.4M in the vault; even if every debt were paid off, $140.2M would remain.
A loss of $13.7M against $0 in annual sales.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 11/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 38/100.
On our five-subject report card, MNPR sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MNPR is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.